Nonpruritic Eczematous Flares During Nemolizumab Therapy: A Case Series

Résumé fourni par la source

L.P. and K.K. declare no conflicts of interest. M.G.L. is an employee of Mount Sinai and receives research funds from: Abbvie, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Clexio, Dermavant Sciences, Eli Lilly Incyte, Inozyme, Johnson & Johnson, Oruka, Pfizer, Sanofi-Regeneron, and UCB, and is a consultant for Added Health, Aikium, Almirall, AltruBio Inc., Alumis, Amgen, Apogee, Arcutis Inc., AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dermsquared, Evommune Inc., Facilitation of International Dermatology Education, Forte biosciences, Galderma, Genentech, Incyte, LEO Pharma, Mayne Pharmaceuticals, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Moonlake, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sunpharma, Takeda, Trevi, and Verrica. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.